Compare Abeona Therapeutics Inc (ABEO) vs Akamai Technologies, Inc. (AKAM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abeona Therapeutics Inc vs Akamai Technologies, Inc. — how do they compare? Abeona Therapeutics Inc trades at $7.4 (market cap $421.19M), while Akamai Technologies, Inc. trades at $122.83 (market cap $16.77B). The key difference: Akamai Technologies, Inc. is far larger — about 39.8× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Akamai Technologies, Inc. nearer its low. Which is the better fit depends on your goals.
| ABEO | AKAM | |
|---|---|---|
Market Cap | $421.19M | $16.77B |
Sector | Health | Technology |
52-Week High | $7.45 | $161.14 |
52-Week Low | $4.17 | $71.97 |
Enterprise Value | $276.10M | $22.75B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.40, down 0.67% on the day, with a bullish technical signal from moving averages. The company reported strong Q1 2026 results with revenue growth and beat EPS estimates for three consecutive quarters. Recent news includes CMS granting NTAP status for ZEVASKYN and expansion of its treatment center network, indicating positive commercial momentum.
Outlook is supported by analyst consensus (66.7% buy ratings) and robust profitability metrics, but risks include high P/S ratio, negative operating cash flow, and a shareholder investigation. The stock's valuation remains attractive on P/E and EV/EBITDA bases, though execution on revenue growth is critical for sustained upside.
Akamai Technologies (AKAM) trades at $123.20, up 4.72% with strong quarterly earnings beats and accelerating cloud infrastructure growth. The stock shows mixed technical signals with bearish moving averages but neutral oscillators. Recent Q2 2026 results exceeded expectations with $1.59 EPS versus $1.57 estimate, driven by 39% growth in Cloud Infrastructure Services. However, net income margins have declined from 14.47% in 2022 to 9.51% currently due to increased infrastructure investments.
Akamai presents a compelling growth story in AI and cybersecurity markets with analyst consensus target of $150.11 suggesting 22% upside potential. Key risks include margin pressure from heavy infrastructure spending and competitive threats in cloud services. The balanced analyst rating distribution (47% Buy, 49% Hold) reflects cautious optimism about the company's strategic positioning amid ongoing profitability challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Akamai Technologies, Inc.
Akamai operates a content delivery network, or CDN, which entails locating servers at the edges of networks so its customers, which store content on Akamai servers, can reach their own customers faster, more securely, and with better quality. Akamai has over 325,000 servers distributed over 4,000 points of presence in more than 1,000 cities worldwide. Its customers generally include media companies, which stream video content or make video games available for download, and other enterprises that run interactive or high-traffic websites, such as e-commerce firms and financial institutions. Akamai also has a significant security business, which is integrated with its core web and media businesses to protect its customers from cyberthreats.
Read more on AKAM →
